Technology market

The Global Recombinant DNA Technology Market is Expected to Exceed US$266.8 Billion by 2030

SEATTLE, July 11, 2022 /PRNewswire/ — According to Consistent market informationthe Global recombinant DNA technology market is estimated at US$145.4 billion in 2022 and should present a CAGR of 7.9% during the forecast period (2022-2030).

Coherent Market Insights logo

Key trends and analysis of the global recombinant DNA technology market:

Increase in research and development activities by major players is expected to drive the market over the forecast period. For example, in June 2021, according to data published by the National Center for Biotechnology Information, hemophilia is a rare disease, treatments for the disorder of hemophilia were previously limited to receiving blood plasma from donors with functional levels of factors coagulation VIII and IX. Advances in DNA technology have led to the production of recombinant factors VIII and IX. Therefore, global data predicts lower utilization of plasma-derived hemophilia treatments in 2022 as developers focus on improving recombinant products and gene therapies.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/893

Main market takeaways:

The Global recombinant DNA technology market is expected to show a CAGR of 7.9% during the forecast period owing to the increasing adoption of inorganic growth strategies such as deals by major market players. In December 2021Lupine Limited, an Indian multinational pharmaceutical company, has entered into an exclusive distribution and marketing agreement with Biomm SA, a biotechnology company from Brazil. Under the terms of the agreement, Biomm would distribute and commercialize the biosimilar product Pegfilgrastim Lupin’ in Brazil. Biomm SA produces human and porcine insulin using recombinant DNA techniques. Lupine had received Food and DruG Administration (US FDA) acceptance of the Biological License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

Among the applications, the therapeutic segment holds a dominant position in the recombinant DNA technology market, due to the increasing number of genetically modified products such as recombinant insulin, erythropoietin and new gene therapies to treat various human diseases. For example, in May 2022, according to an article published by the National Center for Biotechnology Information, erythropoietin-stimulating agents (ESAs) are recombinant versions of the European Patent Office (EPO) produced pharmacologically via recombinant DNA technology in cell cultures . Examples of erythropoietin stimulating agents include epoetin alpha, darbepoetin and methoxy polyethylene glycol-epoetin beta.

Key players operating in the global Recombinant DNA Technology market include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc. and Monsanto Company.

Customization request @ https://www.coherentmarketinsights.com/insight/request-customization/893

Detailed segmentation:

Global Recombinant DNA Technology Market, By Product Type:

Global Recombinant DNA Technology Market, By Application:

  • Therapeutic

  • Agriculture

  • To research

Global Recombinant DNA Technology Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this full report now @ https://www.coherentmarketinsights.com/insight/buy-now/893

Find related trend reports below:

Recombinant Vaccines Marketby type of product (recombinant subunit vaccines, recombinant attenuated vaccines, recombinant vector vaccines), by type of disease (infectious disease, cancer, allergy and others), by end user (recombinant human vaccines and recombinant animal vaccines (poultry, vaccines for pets) vaccines for livestock, pigs and aquaculture)) and by region (North America, Latin America, Europe, Asia Pacific, Middle Eastand Africa) – Size, Share, Prospects & Opportunities Analysis, 2022 – 2030

Recombinant Human Endostatin Marketby Application (Medical Application, Scientific Application), and by Region (North America, Europe, Asia Pacific, Latin America, Middle Eastand Africa) – Size, Share, Prospects and Opportunities Analysis, 2022-2028

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office at Indiahaving a sales office in the financial capital of the world in the United States and sales advisers in UK and Japan. Our customer base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insight in various post-COVID-19 industries and to continuing to deliver measurable and sustainable results to our clients.

Contact us:
Mr Shah
Senior Client Partner – Business Development
Consistent market information
Call:
WE: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
E-mail: [email protected]
Website: https://www.coherentmarketinsights.com
Follow us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Quote

Quote

Show original content:https://www.prnewswire.com/news-releases/global-recombinant-dna-technology-market-to-surpass-us-266-8-billion-by-2030–coherent-market-insights-301583756.html

SOURCE Consistent Market Information